On Invalid Date, Mesoblast (NASDAQ: MESO) reported Q2 2023 earnings per share (EPS) of -$0.14, up 15.15% year over year. Total Mesoblast earnings for the quarter were -$21.92 million. In the same quarter last year, Mesoblast's earnings per share (EPS) was -$0.17.
As of Q4 2023, Mesoblast's earnings has grown year over year. Mesoblast's earnings in the past year totalled -$81.89 million.
What was MESO's revenue last quarter?
On Invalid Date, Mesoblast (NASDAQ: MESO) reported Q2 2023 revenue of $2.14 million up 3.82% year over year. In the same quarter last year, Mesoblast's revenue was $2.22 million.
What was MESO's revenue growth in the past year?
As of Q4 2023, Mesoblast's revenue has grown -26.54% year over year. This is 131.47 percentage points lower than the US Biotechnology industry revenue growth rate of 104.93%. Mesoblast's revenue in the past year totalled $7.50 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.